Abcellera Biologics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $44,854 | $8,955 | $17,084 | $4,235 |
Gross Profit | 44,854 | 8,955 | 17,084 | 4,235 |
EBITDA | -18,229 | -66,313 | -38,833 | -51,902 |
EBIT | -19,499 | -73,549 | -45,893 | -58,507 |
Net Income | -8,945 | -57,119 | -34,727 | -45,621 |
Net Change In Cash | 44,854 | 8,955 | 17,084 | 4,235 |
Free Cash Flow | -44,586 | -61,522 | -45,769 | -22,190 |
Cash | 155,013 | 83,159 | 92,437 | 159,266 |
Basic Shares | 298,707 | 298,875 | 298,508 | 297,692 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $75,128 | $28,833 | $38,025 | $485,424 |
Gross Profit | 75,128 | 28,833 | 38,025 | 418,988 |
EBITDA | -155,424 | -204,148 | -192,158 | 260,167 |
EBIT | -177,595 | -301,146 | -223,052 | 227,065 |
Net Income | -146,412 | -162,857 | -146,398 | 158,519 |
Net Change In Cash | 75,128 | 28,833 | 38,025 | 485,424 |
Cost of Revenue | -76,893 | |||
Free Cash Flow | -174,067 | -186,952 | -121,384 | 204,700 |
Cash | 155,013 | 156,325 | 133,320 | 386,535 |
Basic Shares | 298,707 | 294,327 | 289,166 | 314,827 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.03 |
2025-09-30 | -$0.19 |
2025-06-30 | -$0.12 |
